Holcombe Financial Inc. Acquires New Position in Johnson & Johnson (NYSE:JNJ)

Holcombe Financial Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,333 shares of the company's stock, valued at approximately $337,000. Johnson & Johnson accounts for about 0.3% of Holcombe Financial Inc.'s holdings, making the stock its 23rd largest position.

Other institutional investors also recently added to or reduced their stakes in the company. MRP Capital Investments LLC increased its holdings in Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares during the period. Syverson Strege & Co raised its stake in shares of Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after buying an additional 65 shares during the last quarter. Werba Rubin Papier Wealth Management boosted its stake in shares of Johnson & Johnson by 3.3% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after buying an additional 66 shares during the last quarter. Denali Advisors LLC grew its holdings in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after acquiring an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC lifted its holdings in Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after acquiring an additional 67 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.2 %

Johnson & Johnson stock traded up $0.38 during midday trading on Tuesday, reaching $157.30. The stock had a trading volume of 2,182,816 shares, compared to its average volume of 7,916,864. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock's 50-day simple moving average is $159.53 and its 200 day simple moving average is $154.93. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $379.06 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson's payout ratio is 57.84%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on JNJ shares. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley increased their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Raymond James decreased their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.